This article is more than 5 years old. Information may no longer be current.

Allergan settles Restasis litigation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan has reached a settlement with Famy Care Limited regarding litigation concerning its U.S. patents for Restasis, the company announced in a press release.

Under the agreement, Famy Care litigation concerning the patents for Restasis (cyclosporine ophthalmic emulsion 0.05%) will be dismissed and Famy Care will end its pending petitions for inter partes review, while Allergan will allow the company to market a generic version of the drug in the United States beginning Feb. 27, 2024, or earlier under certain conditions.

Patents for Restasis are listed in the Orange Book and expire Aug. 27, 2024.

Other settlement details were not disclosed.